Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Edema

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    767 result(s) found for: Edema. Displaying page 1 of 39.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2009-010756-10 Sponsor Protocol Number: Index-CSBTE-01-09 Start Date*: 2009-05-19
    Sponsor Name:InDex Pharmaceuticals AB
    Full Title: Effect of an additional single dose of Kappaproct to corticosteroid treated patients with brain edema caused by brain tumor
    Medical condition: Patients with increasing clinical symptoms of brain edema caused by brain tumor or brain metatstasis, on maximum dose of corticosteroids will be asked to participate in the study. The brain edema m...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006121 Brain edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-010536-17 Sponsor Protocol Number: C-09-003 Start Date*: 2009-08-31
    Sponsor Name:ALCON RESEARCH, LTD.
    Full Title: A Clinical Safety and Efficacy Comparison of NEVANAC® 0.1% to Vehicle Following Cataract Surgery in Diabetic Retinopathy Patients
    Medical condition: macular edema following cataract surgery
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051240 Cystoid macular edema LLT
    9.1 10054467 Macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) FR (Completed) DE (Completed) ES (Prematurely Ended) AT (Prematurely Ended) NL (Completed) IT (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-005034-15 Sponsor Protocol Number: DXMT Start Date*: 2022-10-05
    Sponsor Name:HOSPITAL DR JOSEP TRUETA
    Full Title: EFFECT OF DEXAMETASONE ON LOWER LIMB EDEMA IN PATIENTS UNDERTAKEN FOR TOTAL HIP ARTHROPLASTY
    Medical condition: POST -OPERATIVE LOWER LIMB EDEMA
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004867 10014220 Edema extremities LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-005468-25 Sponsor Protocol Number: CRFB002ANO01 Start Date*: 2007-01-24
    Sponsor Name:Retinaklinikken Aleris
    Full Title: A randomized study comparing the safety and efficacy of ranibizumab (Lucentis ®) to sham in patients with macular edema secondary to central retinal vein occlusion (CRVO).
    Medical condition: Macular edema secondary to central retinal vein occlusion (CRVO)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10054467 Macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-003032-37 Sponsor Protocol Number: 08059906 Start Date*: 2007-05-30
    Sponsor Name:OSPEDALE POLICLINICO S. MATTEO
    Full Title: Comparative study on triamcinolone and bevacizumab efficacy in macular edema treatment and in retinic or chorioretinic neovessels treatment
    Medical condition: macular edema
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025415 Macular oedema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-002790-11 Sponsor Protocol Number: V4.0 Start Date*: 2015-06-08
    Sponsor Name:Ludwig-Maximilians Universität München
    Full Title: Evaluation of additional peripheral panretinal LASER-treatment on recurrences of macular edema due to CRVO undergoing anti-VEGF treatment with ranibizumab
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10054467 Macular edema LLT
    20.0 100000004853 10007972 Central retinal vein occlusion LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-000705-30 Sponsor Protocol Number: KONK1001 Start Date*: 2007-05-15
    Sponsor Name:Moorfields Eye Hospital Foundation Trust
    Full Title: efficacy of pegaptanib sodium (macugen) on uveitic cystoid macular oedema: an exploratory study
    Medical condition: uveitic cystoid macular oedema
    Disease: Version SOC Term Classification Code Term Level
    9.1 10058202 Cystoid macular oedema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-006131-53 Sponsor Protocol Number: AU-06104G Start Date*: 2007-08-02
    Sponsor Name:Society (institute) for clinical research
    Full Title: Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study
    Medical condition: Macular edema secondary to branch retinal vein occlusion
    Disease: Version SOC Term Classification Code Term Level
    8.1 10025415 Macular oedema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-023110-30 Sponsor Protocol Number: Octome Start Date*: 2011-04-11
    Sponsor Name:King's College Hospital NHS Foundation Trust
    Full Title: An exploratory phase III prospective open-label clinical study on monthly OCT monitoring of the effects of Ozurdex for macular oedema related to retinal vascular diseases
    Medical condition: Macular oedema related to retinal vascular diseases
    Disease: Version SOC Term Classification Code Term Level
    10025415 Macular oedema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-004292-40 Sponsor Protocol Number: GODIF Start Date*: 2020-02-17
    Sponsor Name:Department of Anesthesia and Intensive Care Medicine, Nordsjællands hospital
    Full Title: Goal directed fluid removal with furosemide in intensive care patients with fluid overload - A randomised, blinded, placebo-controlled trial (GODIF).
    Medical condition: Treatment of fluid overload in critically ill adult patients in intensive care unit.
    Disease: Version SOC Term Classification Code Term Level
    22.1 100000004861 10015766 Extracellular fluid increased LLT
    20.0 100000004861 10016808 Fluid retention in tissues LLT
    24.0 100000004861 10022608 Interstitial fluid increased LLT
    24.1 100000004861 10033303 Overhydration LLT
    20.0 100000004867 10030102 Oedema generalised LLT
    20.1 100000004867 10034611 Peripheral oedema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) NO (Prematurely Ended) FI (Prematurely Ended) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-005056-15 Sponsor Protocol Number: AGO/2013/012 Start Date*: 2014-03-21
    Sponsor Name:UZ Gent
    Full Title: Longterm efficiency and safety of intravitreal injections with bevacizumab in patients with neovascularisation or macular edema.
    Medical condition: Choroidal neovascularisation and chronic macular edema
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10054467 Macular edema LLT
    21.1 10015919 - Eye disorders 10060823 Choroidal neovascularisation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-005045-13 Sponsor Protocol Number: CRFB002EDE20 Start Date*: 2012-04-26
    Sponsor Name:Novartis Pharma GmbH
    Full Title: An open-label, multi-center, 6-month extension study comparing the long-term efficacy and safety of Lucentis (Ranibizumab) intravitreal injections versus Ozurdex (Dexamethasone) intravitreal implan...
    Medical condition: visual impairment due to macular edema following retinal vein occlusion (branch or central)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10054467 Macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-017782-30 Sponsor Protocol Number: Lucentis in CRVO Start Date*: 2010-03-22
    Sponsor Name:Medizinische Universität Graz, Universitäts-Augenklinik
    Full Title: Treatment of macular edema due to central retinal vein occlusion with ranibizumab (Lucentis®).
    Medical condition: This case-series is designed to evaluate the safety and efficacy of intravitreal ranibizumab (Lucentis®) in the treatment of macular edema due to central retinal vein occlusion.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10007972 Central retinal vein occlusion LLT
    12.1 10054467 Macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2008-004899-50 Sponsor Protocol Number: 2200/07 Start Date*: 2008-05-13
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: OCT analysis of cystoid macular edema in uveitis patients undergoing anti-inflammatory treatment
    Medical condition: Cystoid macular edema in uveitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051240 Cystoid macular edema LLT
    9.1 10046851 Uveitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-006063-22 Sponsor Protocol Number: FOM-ICI01-2011 Start Date*: 2012-02-03
    Sponsor Name:Fundación Oftalmológica del Mediterráneo
    Full Title: Prevención del edema macular diabético en pacientes con retinopatía diabética tratados con Ozurdex® tras la cirugía de cataratas
    Medical condition: edema macular diabético en pacientes con retinopatía diabética
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10025415 Macular oedema PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-003193-17 Sponsor Protocol Number: BAY86-5321/17514 Start Date*: 2016-08-30
    Sponsor Name:Bayer AG
    Full Title: A multi center, single arm, interventional Phase 4 study to evaluate a Treat and Extend regimen of intravitreal aflibercept for treatment of macular edema secondary to central retinal vein occlusion
    Medical condition: Macular edema secondary to CRVO
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10025415 Macular oedema PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) DK (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-001761-11 Sponsor Protocol Number: 300488 Start Date*: 2015-08-31
    Sponsor Name:The Department of Cardiothoracic and Vascular Surgery, Aarhus University Hospital
    Full Title: Lymphatic dysfunction as a cause of calcium channel blocker oedema in post-menopausal women
    Medical condition: Calcium channel antagonist induced peripheral edema in post-menopausal women. We hypothesize that this condition is partly due to impaired lymphatic function in these patients.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004867 10067033 Drug side effect LLT
    18.0 100000004867 10034570 Peripheral edema LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2011-000369-11 Sponsor Protocol Number: 0624-203 Start Date*: 2011-07-07
    Sponsor Name:ViroPharma Incorporated
    Full Title: Open-label, single-dose study to evaluate the response and pharmacokinetics/pharmacodynamics of different doses of Cinryze® [C1 Inhibitor (human)] for treatment of acute angioedema attacks in child...
    Medical condition: Acute angioedema attacks in children less than 12 years of age with hereditary angioedema.
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004858 10037735 Quincke's oedema LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-002635-28 Sponsor Protocol Number: OFT-Campos01-12 Start Date*: 2013-04-19
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: ASSESSMENT OF THE EFFICACY OF SUBTENON NATURAL LEUCOCYTIC INTERFERON-α (IFNα) FOR THE TREATMENT OF DIABETIC MACULAR EDEMA (DME): A PILOT STUDY.
    Medical condition: DIABETIC MACULAR EDEMA (DME)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004853 10057934 Diabetic macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001670-28 Sponsor Protocol Number: BER-1272-0058-I Start Date*: 2013-03-18
    Sponsor Name:Medizinische Fakultät der Technischen Universität München
    Full Title: Angiotensin Converting Enzyme Inhibitor (ACE) Induced Angioedema BERINERT Randomized, double-blind, two arms, multicenter, Phase III study of Berinert for treatment of ACE induced Angioedema
    Medical condition: Angiotensin – Converting – Enzyme – Inhibitors (ACEi) are used in the treatment of several types of cardiovascular and renal diseases. A known side effect of ACEi are angioedema of the head and ...
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004870 10002425 Angioedemas HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 23 00:05:46 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA